Dima Sobko / Shutterstock.com
Hedge fund manager Kyle Bass has filed another inter partes review (IPR), teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Diprivan, Patent Trial and Appeal Board, USPTO, Kyle Bass, Coalition for Affordable Drugs, Fresenius Kabi, IPR, Inter Partes Review